Today, the decades-long commitment to “Research for a Cure” by NFCR and NFCR-funded scientists is making a difference in the lives of millions of cancer patients and their families worldwide. Get to know the scientists who are leading the way into a new era of cancer prevention, detection and treatment. Together, we will find a cure for all cancers!
Filter By :
Collaborative Research Grants
NFCR's team science approach aims to investigate the new frontiers of cancer research which will lead to future breakthroughs. Combining experts with differing specialties allows new paths to discoveries and innovations.
The research team tries to identify the major ‘drivers’ of resistance to tyrosine kinase inhibitors in non-small cell lung cancer to develop new methods for patients when drug resistance occurs.
The research team will use a “systems biology” approach paired with single-cell technologies to identify the factors that restrain the tumor infiltration and treatment effects of CAR-T cells for GBM.
The research team will use cutting-edge single-cell technology and patient-derived tumor samples to address the deadly skin cancer Merkel cell carcinoma (MCC) treatment challenges.
The research team investigates SerRS, a suppressor of breast cancer and its metastasis. Their work may lead to novel therapeutic applications for brain, esophageal, kidney, rectal, stomach, and thyroid cancers.
The research team will apply the latest genetic engineering technology to patient-derived disease models to develop a novel CAR-T cell therapy for pancreatic cancers.
The research team collaborates to identify therapeutic targets that may lead to novel therapies for the most deadly subtype of breast cancer, triple negative breast cancer (TNBC).
The research team investigates tRNA fragments located in special cell parts, with the potential of new biomarkers that indicate the risk of metastasis and save more lives.
The research team is doing innovative research to improve the treatment outcomes for breast cancer, including difficult-to-treat triple-negative breast cancer, by utilizing single-cell multi-omics technology.
The research team aims to identify the link between losing a piece of DNA from oral cancer cells and their capability to escape from immune cell attacks.
The research team will combine molecular imaging technology, photodynamic therapy, and image-guided surgery to develop better triple-negative breast cancer treatment approaches.
The research team focuses on the combined technologies of gene and cell replacement therapies in retinal diseases, which may apply to patients with other eye diseases to restore their vision.
The research team will employ 2-D and 3-D in vitro cell culture techniques and clinical tumor samples to decipher the role of protein-sugar interaction, or protein glycosylation, in a tumor’s brain metastases and drug resistance.
AIM-HI Translational Research Grants
NFCR provides Translational Research Grants to our non-profit partner, AIM-HI Accelerator Fund, to bridge the gap between innovations in the laboratory environment to the clinical development of new treatments and technologies. This translational research effort aims to accelerate early-stage oncology startups to bring new therapies and diagnostic tools to patients.
Select Past Supported Scientists
Jacqueline K. Barton, Ph.D.
Jean Bennett, M.D., Ph.D.
Robert C. Bast, Jr., M.D.
Webster K. Cavenee, Ph.D.
Esther H. Chang, Ph.D.
Laurence J.N. Cooper, M.D., Ph.D.
Harold F. Dvorak, M.D.
Kathryn B. Horwitz, Ph.D.
Susan Band Horwitz, Ph.D.
Laurence Hurley, Ph.D.
Jin Jen, M.D., Ph.D.
Wayne Marasco, M.D., Ph.D.
William L. Jorgensen, Ph.D.
Lawrence Marnett, Ph.D.
Alanna Schepartz, Ph.D.
Alice T. Shaw, M.D., Ph.D.
Helmut Sies, M.D.
Amos B. Smith III, Ph.D.
Daniel D. Von Hoff, M.D., FACP
Wei Zhang, Ph.D.
Michael B. Sporn, M.D.
W. K. Alfred Yung, M.D.
